JPRN-UMIN000018517招募中3 期
Cross over trial of GD and GP therapy in metastatic urothelial carcinoma after the failure of cisplatin-based chemotherapy: randomised phase 3 trials - Cross over trial of GD and GP therapy in metastatic urothelial carcinoma
agoya City University Graduate School of Medical Sciences0 个研究点目标入组 60 人开始时间: 2015年8月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •exclusion criteria patients were below: the patients who had allergy to gemcitabine, and , or taxane derivatives, or patients suspected interstitial lung disease by X ray, or patients who had past history of radiation theapy in chest, or patients suspected infection diseases, or patients who had the possibility of pregnancy, or patients who had uncontrolled cancer diffferent from urothelial cancer.
研究者
相似试验
已完成
不适用
Anti-tumor effect and safety of GDP therapy (gemcitabine, dexamethasone, and cisplatin) in patients with relapsed or refractory non-Hodgkin lymphomarelapsed or refractory non-Hodgkin lymphomaJPRN-UMIN000011604Hiroshima University25
未知
3 期
Phase 3 study of GGS in patients with CSS/AGAChurg-Strauss Syndrome (CSS) / Allergic Granulomatous Angiitis (AGA)JPRN-jRCT2080220238TEIJIN PHARMA LIMITED21
进行中（未招募）
1 期
An early phase clinical study to investigate the combination of chemotherapy (Gemcitabine) and the study drug Atu027 in patients with advanced or metastatic pancreas cancerEUCTR2012-004429-26-DESilence Therapeutics GmbH
撤回
2 期
GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTCIntrahepatic CholangiocarcinomaNCT05019677Fudan University
进行中（未招募）
2 期
GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTCBiliary Tract CarcinomaNCT05023109Shanghai Zhongshan Hospital45